Bionano Genomics (NASDAQ:BNGO) Shares to Reverse Split on Monday, January 27th

Bionano Genomics, Inc. (NASDAQ:BNGO) shares are set to reverse split before the market opens on Monday, January 27th. The 1-60 reverse split was announced on Wednesday, January 22nd. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, January 24th.

Bionano Genomics Stock Performance

BNGO traded down $0.05 during trading on Thursday, reaching $0.13. 31,894,418 shares of the company’s stock were exchanged, compared to its average volume of 19,639,521. The company’s fifty day simple moving average is $0.23 and its 200-day simple moving average is $0.37. The stock has a market capitalization of $15.47 million, a P/E ratio of -0.06 and a beta of 2.22. The company has a debt-to-equity ratio of 0.07, a current ratio of 1.43 and a quick ratio of 0.99. Bionano Genomics has a 1 year low of $0.13 and a 1 year high of $1.36.

Wall Street Analysts Forecast Growth

Separately, LADENBURG THALM/SH SH downgraded shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a research report on Friday, November 15th.

Hedge Funds Weigh In On Bionano Genomics

Several large investors have recently made changes to their positions in BNGO. Carret Asset Management LLC increased its holdings in Bionano Genomics by 89.0% in the third quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock valued at $39,000 after buying an additional 40,055 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of Bionano Genomics in the 3rd quarter valued at about $46,000. Geode Capital Management LLC raised its holdings in Bionano Genomics by 47.3% in the 3rd quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock worth $401,000 after purchasing an additional 283,639 shares during the period. Finally, Armistice Capital LLC purchased a new position in Bionano Genomics during the second quarter worth approximately $1,138,000. 11.35% of the stock is currently owned by institutional investors and hedge funds.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.